<DOC>
	<DOCNO>NCT01648465</DOCNO>
	<brief_summary>The purpose study explore efficacy safety everolimus administer first-line treatment newly-diagnosed patient advance inoperable Gastrointestinal ( GI ) pancreatic neuroendocrine tumor .</brief_summary>
	<brief_title>Study Everolimus Treatment Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Adenoma , Islet Cell</mesh_term>
	<mesh_term>Digestive System Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Male female , age ≥ 18 year age . 2 . Newly diagnose patient biopsyproven well moderately differentiate advanced ( metastatic unresectable ) GI pancreatic neuroendocrine tumor . 3 . Measurable disease base RΕCIST 1.1 use triphase CT scan multiphase MRI scan . 4 . Patients ki67 measurement &lt; 20 % prior enrollment study . 5 . Performance status 02 WHO scale . 6 . Adequate bone marrow function show : ANC ≥ 1.5 x 10^9/L , Platelets ≥ 100 x 10^9/L , Hemoglobin &gt; 9 g/dL . 7 . Adequate liver function show : Serum bilirubin ≤ 1.5 x ULN , ALT/SGPT AST/SGOT ≤ 2.5 x ULN ( ή ≤ 5 x ULN patient know liver metastasis ) , INR &lt; 1.3 ( INR &lt; 3 patient treated anticoagulant ) . 8 . Adequate renal function show : serum creatinine ≤ 1.5 x ULN . 9 . Fasting serum cholesterol ≤ 300 mg/dL ≤ 7.75 mmol/L fast triglyceride ≤ 2.5 x ULN . Note : In case one upper limit exceed , patient enrollment perform upon proper antilipidemic treatment initiation . 10 . Women childbearing potential , negative serum urine pregnancy test within 48 hour prior first study treatment administration . 11 . Signed informed consent form obtain trial related activity , include screen phase , accord applicable law ICH/GCP requirement . 12 . Signed informed consent use biological genetic material 1 . Patients poorly differentiate undifferentiated GI pancreatic neuroendocrine carcinoma . 2 . Previous concurrent cytotoxic chemotherapy , immunotherapy radiotherapy . 3 . Hepatic artery embolization cryoablation hepatic metastasis within 1 month study enrollment . 4 . Prior therapy mTOR inhibitor ( example sirolimus , temsirolimus , everolimus ) . 5 . Patients receive chronic treatment corticosteroid immunosuppressive . 6 . Uncontrolled diabetes mellitus define fast serum glucose &gt; 1.5 x ULN . 7 . Patients severe and/or uncontrolled medical condition : unstable angina pectoris , symptomatic congestive heart failure NYHA class II , III , IV , myocardial infarction ≤ 6 month prior enrollment , serious uncontrolled cardiac arrhythmia ( LVEF &lt; 50 % ) active uncontrolled severe infection cirrhosis , chronic active hepatitis , chronic persistent hepatitis inadequate hepatic function ( ALT/SGPT AST/SGOT &gt; 5 x ULN ) inadequate bone marrow ( ANC &lt; 1.5 x 10^9/L , platelet &lt; 100 x 10^9/L , hemoglobin ≤ 9 g/dL ) renal failure ( serum creatinine &gt; 1.5 x ULN severely impair lung function ( patient need oxygen support ) . 8 . Active bleed diathesis oral treatment vitamin K antagonist ( apart lowdose coumadine ) . 9 . Performance status ≥ 3 WHO scale . 10 . Patients known history HIV seropositivity . Screening HIV infection baseline require . 11 . No prior concurrent malignancy allow except follow : adequately treat basal cell squamous cell skin cancer , treat situ cancer cervix , cancer patient disease free ≥ 3 year . 12 . Patients within 28 day postmajor surgery ( e.g . intrathoracic , intrabdominal intrapelvic ) , open biopsy , significant traumatic injury avoid wound heal complication . Minor procedure percutaneous biopsy placement vascular access device require 7 day prior study entry . Note : Patients must recover acute effect surgery prior enrollment . 13 . Female patient pregnant nursing ( lactate ) . 14 . Adults reproductive potential use effective birth control method . If barrier contraceptive measure use , must continue throughout study sex . 15 . Patients participate another clinical trial receive investigational drug . 16 . Patients unwilling unable comply protocol investigator 's discretion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>metastatic</keyword>
	<keyword>unresectable</keyword>
	<keyword>well moderately differentiate</keyword>
	<keyword>advanced</keyword>
</DOC>